Cyteir Therapeutics attracts $80m Series C
Cyteir Therapeutics, a developer of next-generation synthetic lethal therapies for cancer, has raised $80 million in Series C financing.
Cyteir Therapeutics, a developer of next-generation synthetic lethal therapies for cancer, has raised $80 million in Series C financing.